caa a22 4500 605490716 CHVBK 20210128100506.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10147-015-0838-z doi (NATIONALLICENCE)springer-10.1007/s10147-015-0838-z Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations [Elektronische Daten] [Yuhei Yokoyama, Makoto Sonobe, Tetsu Yamada, Masaaki Sato, Toshi Menju, Akihiro Aoyama, Toshihiko Sato, Fengshi Chen, Mitsugu Omasa, Hiroshi Date] Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials. However, the effect of gefitinib treatment for recurrent lung cancers with EGFR gene mutations after complete resection and the influence of the timing of such treatment have not been fully elucidated in a practical setting. Methods: We investigated 64 patients (median age: 68years; men: 22; women: 42; adenocarcinoma: 61; adenosquamous cell carcinoma: 2; combined large cell neuroendocrine carcinoma: 1) with recurrent lung cancer after complete resection who received gefitinib for the recurrent lesions and in whom the tumors had EGFR gene mutations. Progression-free survival, response rate, and safety were analyzed. Results: Complete response and partial response were achieved in 2 patients and in 42 patients, respectively (objective response rate: 69%). Stable disease was obtained in 16 patients, the disease control rate was 94%, and median progression-free survival was 16months. The timing of gefitinib treatment (first line, second line, or later) and the type of EGFR gene mutation present did not influence progression-free survival. However, a smaller number of recurrent sites at the start of gefitinib treatment was linked to better progression-free survival. Hematologic and nonhematologic toxicities were generally mild, but 1 patient experienced interstitial lung disease. Conclusions: Our results suggest that gefitinib treatment for recurrent lung cancer with geneEGFR mutations is a useful option in a practical setting, irrespective of the timing of such treatment and the type of EGFR gene mutation present. Japan Society of Clinical Oncology, 2015 Lung cancer nationallicence Epidermal growth factor receptor nationallicence Postoperative recurrence nationallicence Gefitinib nationallicence Yokoyama Yuhei Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Sonobe Makoto Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Yamada Tetsu Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Sato Masaaki Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Menju Toshi Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Aoyama Akihiro Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Sato Toshihiko Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Chen Fengshi Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Omasa Mitsugu Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut Date Hiroshi Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1122-1129 1341-9625 20:6<1122 2015 20 10147 https://doi.org/10.1007/s10147-015-0838-z text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0838-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yokoyama Yuhei Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Sonobe Makoto Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Yamada Tetsu Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Sato Masaaki Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Menju Toshi Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Aoyama Akihiro Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Sato Toshihiko Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Chen Fengshi Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Omasa Mitsugu Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 700 1- Date Hiroshi Department of Thoracic Surgery, Kyoto University Hospital, Shogoin-Kawahara-cho 54, Sakyo-ku, 606-8507, Kyoto, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1122-1129 1341-9625 20:6<1122 2015 20 10147